Home/Advesya/Erik Rutjens

ER

Erik Rutjens

Chief Technology Officer

Therapeutic Areas

Oncology Autoimmune Diseases

Advesya Pipeline

Drug	Indication	Phase
ADV-101	Oncology (e.g., Esophageal Cancer)	Phase 1
CCTx-001	Oncology (likely), Autoimmune (potential)	Phase 1

Leadership Team at Advesya

Ksenija Pavletic

Chief Executive Officer, Board Member

Chief Medical Officer

Richard C. A. Sainson

Chief Scientific Officer

Chief Financial Officer

Dr. Christophe Ferrand

Academic Founder, Board Member

Dr. Marina Deschamps

Academic Founder

View full Advesya profile